• Vaccine Name: HBVAXPRO
• Target Pathogen: Hepatitis B virus
• Target Disease: Hepatitis B
• Manufacturer: (Sanofi Pasteur MSD
• Type: Recombinant vector vaccine
• Status: Licensed
• Location Licensed: France
• Host Species for Licensed Use: Human
• Antigen: hepatitis B surface antigen
• Immunization Route: Intramuscular injection (i.m.)
• Approved Age for Licensed Use: Patients aged ≥18 years.
• Description: HBVAXPRO Is a recombinant vector vaccine with a single adjuvant HBV vaccine with aluminium hydroxyphosphate sulfate administered intramuscularly in the deltoid muscle. (Horta et al., 2022)

Human Response

• Vaccination Protocol: Patients were vaccinated with HBVAXPRO® 40 at 0, 1 and 6 months (Horta et al., 2022).
• Efficacy: The results of our study show that HBVAXPRO is effective and safe in patients with chronic liver disease.